AXSM vs. NVO
Compare and contrast key facts about Axsome Therapeutics, Inc. (AXSM) and Novo Nordisk A/S (NVO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: AXSM or NVO.
Correlation
The correlation between AXSM and NVO is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
AXSM vs. NVO - Performance Comparison
Loading data...
Key characteristics
AXSM:
0.91
NVO:
-1.13
AXSM:
1.75
NVO:
-1.72
AXSM:
1.20
NVO:
0.78
AXSM:
1.29
NVO:
-0.83
AXSM:
4.03
NVO:
-1.50
AXSM:
10.58%
NVO:
32.77%
AXSM:
45.88%
NVO:
42.92%
AXSM:
-86.65%
NVO:
-71.29%
AXSM:
-21.38%
NVO:
-53.47%
Fundamentals
AXSM:
$5.29B
NVO:
$284.34B
AXSM:
-$5.77
NVO:
$3.52
AXSM:
0.00
NVO:
0.97
AXSM:
12.25
NVO:
0.94
AXSM:
99.51
NVO:
13.78
AXSM:
$432.16M
NVO:
$303.14B
AXSM:
$395.36M
NVO:
$255.65B
AXSM:
-$266.14M
NVO:
$154.08B
Returns By Period
In the year-to-date period, AXSM achieves a 28.00% return, which is significantly higher than NVO's -20.83% return.
AXSM
28.00%
3.68%
17.14%
41.49%
50.69%
4.98%
N/A
NVO
-20.83%
15.39%
-31.77%
-48.17%
9.18%
17.53%
11.03%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
AXSM vs. NVO — Risk-Adjusted Performance Rank
AXSM
NVO
AXSM vs. NVO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Axsome Therapeutics, Inc. (AXSM) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
AXSM vs. NVO - Dividend Comparison
AXSM has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 2.41%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AXSM Axsome Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 2.41% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
Drawdowns
AXSM vs. NVO - Drawdown Comparison
The maximum AXSM drawdown since its inception was -86.65%, which is greater than NVO's maximum drawdown of -71.29%. Use the drawdown chart below to compare losses from any high point for AXSM and NVO. For additional features, visit the drawdowns tool.
Loading data...
Volatility
AXSM vs. NVO - Volatility Comparison
The current volatility for Axsome Therapeutics, Inc. (AXSM) is 9.58%, while Novo Nordisk A/S (NVO) has a volatility of 12.68%. This indicates that AXSM experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
AXSM vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Axsome Therapeutics, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AXSM vs. NVO - Profitability Comparison
AXSM - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Axsome Therapeutics, Inc. reported a gross profit of 111.67M and revenue of 121.46M. Therefore, the gross margin over that period was 91.9%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a gross profit of 65.20B and revenue of 78.09B. Therefore, the gross margin over that period was 83.5%.
AXSM - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Axsome Therapeutics, Inc. reported an operating income of -56.98M and revenue of 121.46M, resulting in an operating margin of -46.9%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported an operating income of 38.79B and revenue of 78.09B, resulting in an operating margin of 49.7%.
AXSM - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Axsome Therapeutics, Inc. reported a net income of -59.41M and revenue of 121.46M, resulting in a net margin of -48.9%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a net income of 29.03B and revenue of 78.09B, resulting in a net margin of 37.2%.